Comprehensive Analysis of the Prognosis and Correlations With Immune Infiltration of S100 Protein Family Members in Hepatocellular Carcinoma

Susu Zheng\textsuperscript{1,2,}\textsuperscript{*}, Linxia Liu\textsuperscript{3,}\textsuperscript{*}, Tongchun Xue\textsuperscript{2,}, Chuyu Jing\textsuperscript{2}, Xin Xu\textsuperscript{2}, Yanfang Wu\textsuperscript{1}, Meixia Wang\textsuperscript{1}, Xiaoying Xie\textsuperscript{1,2} and Boheng Zhang\textsuperscript{1,2,4}\textsuperscript{*}

\textsuperscript{1}Xiamen Branch, Department of Hepatic Oncology, Zhongshan Hospital, Fudan University, Xiamen, China, \textsuperscript{2}Key Laboratory for Carcinogenesis and Cancer Invasion, Zhongshan Hospital, Shanghai Medical School, The Liver Cancer Institute, The Chinese Ministry of Education, Fudan University, Shanghai, China, \textsuperscript{3}School of Nursing and Health Management, Shanghai University of Medicine and Health Sciences, Shanghai, China, \textsuperscript{4}Center for Evidence-Based Medicine, Shanghai Medical School, Fudan University, Shanghai, China

S100 protein family members (S100s) are commonly dysregulated in various tumors including hepatocellular carcinoma (HCC). However, the diverse expression, mutation, prognosis and associations with immune infiltration of S100s in HCC have yet to be analyzed. Herein we investigated the roles of S100s in HCC from the Oncomine, Gene Expression Profiling Interactive Analysis (GEPIA), Human Protein Atlas, Kaplan-Meier Plotter, cBioPortal and TIMER databases. Compared with para-cancer tissues, the expression levels of S100A4/S100A6/S100A10/S100A11/S100A13/S100A14/S100P were higher in HCC tissues, while the expression levels of S100A8/S100A9/S100A12 were decreased in tumor tissues. The mRNA levels of S100A2/S100A7/S100A7A/S100A8/S100A9/S100A11 were correlated with advanced tumor stage. Besides, higher mRNA expressions of S100A6/S100A10/S100A11/S100A13/S100A14/S100P were shown to have shorter overall survival (OS), while higher expression of S100A12 was associated with favorable OS. Further, the mutation rate of S100s was investigated, and the high mutation rate (53%) was associated with shorter OS. Additionally, the expressions of S100s were found to be significantly associated with various immune infiltrating cells. Hence, our results showed that S100A6/S100A10/S100A11/S100A12/S100A13/S100A14/S100P may be regarded as new prognostic or therapeutic markers and S100s inhibitors may be helpful in the combination of immunotherapies.

Keywords: S100 protein family, hepatocellular carcinoma, prognosis, immune infiltrates, mutations

INTRODUCTION

Hepatocellular carcinoma (HCC) comprises nearly 80% of primary liver cancer and is the sixth most common and fourth deadly malignancy globally (Bray et al., 2018). Surgical resection or liver transplantation are the only potential measures for radical cure, while these measures are only limited to a small subset of patients. In fact, nearly 75% patients were belonging to middle-late
stage of HCC when first diagnosed, and the 5 year survival rate was dismal (Allemani et al., 2015; Katsanos et al., 2017). Thus, novel prognosis or therapeutic biomarkers for HCC are imperative.

S100 protein family members (S100s) are well-known for their calcium-binding properties, and widely involved in a variety of physiological and pathological processes, including inflammation, cell proliferation, apoptosis and cancer development. Until now, there are at least twenty members that have been reported (S100A1-S100A14, S100A7A, S100A16, S100B, S100P, S100G, S100Z) (Allgower et al., 2020). The expression of S100s are commonly dysregulated in human malignancies, including HCC (Bresnick et al., 2015; Xue et al., 2015). The expression and role of S100s display a distinctive pattern in different cancer types. For instance, S100A2 plays a tumor-suppress role in most cancers including breast cancer, melanoma, gastric cancer etc., but may have an opposite role in lung cancer (Hountis et al., 2014). S100s have been shown to have complex roles in HCC. Apart from S100A5, S100A7, S100A7A, S100A12, S100A13, S100A16, S100B, S100P, S100G, S100Z, the rest family members, such as S100A1, S100A2, S100A3, S100A4, S100A6, S100A8, S100A9, S100A10, S100A11, S100A14, and S100P are shown to be expressed in HCC (Wang et al., 2001; Kittaka et al., 2008; Hua et al., 2011; Luo et al., 2013; Yan et al., 2013; Zhao et al., 2013; De Ponti et al., 2015; Tao et al., 2017; Guo et al., 2018). Furthermore, the protein expressions of S100A1, S100A4, S100A6, S100A14 and S100P detected by immunohistochemistry were reported to be associated with short survival of HCC patients. Nevertheless, some S100 family members, such as S100A5, S100A7, S100A7A, S100A13, S100A16, S100B, S100G, and S100Z have been rarely studied in HCC. Moreover, the role of S100s in affecting the immune microenvironment in HCC has yet to be explored. However, due to small sample size in some studies, these results remained questionable. As far as we know, bioinformatics analysis has yet to be operated to discover the distinct properties of S100s in HCC. Through the help of integrated bioinformatics analysis, we are now able to analyze thousands of interested genes through multiple databases at one time (Liu et al., 2020). On the basis of in-depth analysis, we analyzed the expressions, mutations, predictive signaling pathways and associations with immune infiltration of different S100s in patients with HCC and further explored their possible functions, different prognostic roles and the associations with immune infiltrates in HCC.

**MATERIALS AND METHODS**

**Ethics Statement**

The study was approved by the Ethics Committee of Zhongshan Hospital. All the data were collected from published databases. It was then confirmed that all written informed consent was obtained.

**ONCOMINE Database**

Oncomine database, an online database¹ was utilized to analyze the mRNA expression of 20 S100s in different types of cancer including HCC (Rhodes et al., 2004). Students’ t-test was applied to get a p-value (cutoff p-value: 0.001, cutoff fold change: 1.5).

**GEPIA Dataset**

GEPIA, an online tool that contains the RNA expression of 9,736 tumors and 8,587 normal samples from the Cancer Genome Atlas and the Genotype Tissue Expression (GTEx) projects² (Tang et al., 2017). The dataset is capable of providing tumor/norval differential expression analysis, survival analysis, correlation analysis and so on. HCC patients were divided into high and low expression groups according to their median value of mRNA expression. The cutoffs of p-value and fold change were defined as following: p-value: 0.01, fold change: 1.

**Human Protein Atlas**

The Human Protein Atlas, an online tool which contains protein expression data (detected by immunohistochemistry) from 17 different human cancers³, was applied to study the protein levels of S100s in HCC (Asplund et al., 2012). Here, we compared the protein expression of different S100s between HCC tissues and normal tissues by immunohistochemistry.

**The Kaplan-Meier Plotter**

The Kaplan-Meier Plotter, a website that contains gene expression data and survival information of various cancers⁴ was used to analyze the prognostic value of different S100s in HCC (Gyorffy et al., 2013). The HCC samples were divided into high and low expression groups according to their median value of mRNA expression and then analyzed by Kaplan-Meier survival plot. Statistically significant was considered when a p < 0.05.

**cBioPortal**

cBioPortal, an online tool that contains multidimensional cancer genomics data⁵ was used to analyze genetic mutations in S100s and their associations with survival (Gao et al., 2013). The HCC dataset which included 360 patients were chosen for mutation analysis. The co-expression and network was also analyzed.

**Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) Analysis**

Fifty interactors based on the cBioPortal tool were further explored by GO and KEGG. The functions and predicted pathways were analyzed in the Database for Annotation, Visualization and Integrated Discovery (DAVID)⁶ (Huang et al., 2009). We then used the R package “ggplot” and “stringr” to perform GO and KEGG pathway enrichment analyses.

---

¹https://www.oncomine.org
²http://gepia.cancer-pku.cn/
³https://www.proteinatlas.org
⁴www.kmplot.com
⁵www.cbioportal.org
⁶https://david.ncifcrf.gov/
FIGURE 1 | The transcription levels of S100 family members (S100s) in different types of cancers (Oncomine database). Cells in red color represents the overexpression of interested gene, while lowexpression shows in blue. The numbers in these cells represents the numbers of datasets which satisfies the threshold: p-value: 0.001, fold change: 1.5. The levels of S100A4/S100A6/S100A10/S100A11/S100A13/S100A14/S100P were higher in tumor than in normal liver samples, while S100A8 were downregulated.

TABLE 1 | Significant changes of S100s expression in transcription level between HCC and normal liver tissues (ONCOMINE database).

| Types of liver cancer vs. normal tissue | Fold change | P-value | t-test | Sources and/or References |
|---------------------------------------|-------------|---------|--------|---------------------------|
| S100A1 Hepatocellular carcinoma       | −1.94       | 8.52E-11| −6.787 | Chen liver                |
| S100A2 Hepatocellular carcinoma       | NA          | NA      | NA     | NA                        |
| S100A3 Hepatocellular carcinoma       | NA          | NA      | NA     | NA                        |
| S100A4 Hepatocellular carcinoma       | 1.77        | 3.44E-06| 4.972  | Mas liver                 |
| S100A5 Hepatocellular carcinoma       | NA          | NA      | NA     | NA                        |
| S100A6 Hepatocellular carcinoma       | 2.823       | 9.16E-04| 3.502  | Roessler liver            |
| S100A7 Hepatocellular carcinoma       | NA          | NA      | NA     | NA                        |
| S100A8 Hepatocellular carcinoma       | −2.672      | 8.22E-13| −7.602 | Chen liver                |
| S100A9 Hepatocellular carcinoma       | NA          | NA      | NA     | NA                        |
| S100A10 Hepatocellular carcinoma      | −14.197     | 3.38E-05| −5.235 | Wurmbach liver            |
| S100A11 Hepatocellular carcinoma      | −3.969      | 9.31E-08| −6.089 | Mas liver                 |
| S100A12 Hepatocellular carcinoma      | 1.998       | 3.63E-12| 7.38   | Chen liver                |
| S100A13 Hepatocellular carcinoma      | 2.209       | 1.27E-04| 4.079  | Roessler liver            |
| S100A14 Hepatocellular carcinoma      | 1.926       | 2.46E-13| 9.278  | Mas liver                 |
| S100A15 Hepatocellular carcinoma      | 2.285       | 2.08E-05| 5.326  | Wurmbach liver            |
| S100A16 Hepatocellular carcinoma      | −2.045      | 1.58E-04| −9.281 | Chen liver                |
| S100A17 Hepatocellular carcinoma      | 1.506       | 5.00E-03| 2.706  | Roessler liver            |
| S100A18 Hepatocellular carcinoma      | 1.654       | 3.38E-07| 5.733  | Mas liver                 |
| S100A19 Hepatocellular carcinoma      | 1.926       | 2.46E-13| 9.278  | Mas liver                 |
| S100A20 Hepatocellular carcinoma      | 2.285       | 2.08E-05| 5.326  | Wurmbach liver            |
| S100A21 Hepatocellular carcinoma      | NA          | NA      | NA     | NA                        |
| S100A22 Hepatocellular carcinoma      | 2.285       | 2.08E-05| 5.326  | Wurmbach liver            |

NA, not available. A P value < 0.05 was considered to be statistically significant and was shown in bold print.
TIMER Database

TIMER, an online tool\(^7\) that contains comprehensive analysis of immune infiltrates in different types cancers was used to analyze the association between S100s and immune infiltrates in HCC. The associations between gene markers and various immune cells were also recorded (Li et al., 2017). Spearman tests were used for analyzing the correlation coefficients.

\(^7\)https://cistrome.shinyapps.io/timer/

RESULTS

Expression Levels of S100s and Their Relationship With Clinicopathological Parameters of Patients With HCC

MRNA levels of twenty S100s in cancers were detected by exploring Oncomine databases (Figure 1 and Table 1). The mRNA expression levels of S100A4/S100A6/S100A10/S100A11/S100A13/S100A14/S100P were higher in tumor than in normal liver samples, while S100A8/S100A9/S100A12 were downregulated (A, scatter diagram; B, box plot; \(p < 0.01\)).

FIGURE 2 | The mRNA levels of S100s in hepatocellular carcinoma (HCC) (GEPIA database). The levels of S100A4/S100A6/S100A10/S100A11/S100A13/S100P were higher in tumor than in normal liver samples, while S100A8/S100A9/S100A12 were downregulated (A, scatter diagram; B, box plot; \(p < 0.01\)).
were significantly upregulated in patients with HCC from multiple datasets, while S100A8 were downregulated ($p = 0.001$, fold change $= 1.5$). However, the other members did not differ significantly in HCC as assessed in the multiple datasets (Chen et al., 2002; Wurmbach et al., 2007; Mas et al., 2009; Roessler et al., 2010). We next utilized the GEPIA dataset to analyze the expression profile of twenty S100s. The gene expression profile analysis demonstrated that the levels of S100A4/S100A6/S100A10/S100A11/S100A13/S100P were higher in tumor than in normal liver samples. Moreover, the transcription levels of S100A8, S100A9, and S100A12 were decreased ($p = 0.01$, Figure 2). Associations between S100s mRNA levels and tumor stage were also analyzed. S100A2/S100A7/S100A11/S100A8/S100A9/S100A11 groups were shown to be statistically significant (Figure 3). After checking the mRNA levels of S100s in HCC, the Human Protein Atlas was applied to explore the protein expression of S100s in HCC. As displayed in Figure 4, low protein expression of S100A7A was found in normal liver tissues, all the other S100s proteins were not detected in normal liver tissues. S100A5 protein expression was not shown by the database. Low protein expressions of S100A4/S100A11/S100B were observed in HCC tissues. Medium protein expressions of S100A1/S100A6/S100A7/S100A7A/S100A10/S100G/S100P were observed in HCC tissues. Protein expressions of the other members of S100s were not detected in HCC tissues. However, due to the small HCC sample size of immunohistochemistry results in the Human Protein Atlas, the results obtained should be verified further.

**Prognostic Roles of S100s in HCC**

We explore the prognostic roles of distinct S100s in patients of HCC by using the Kaplan-Meier Plotter tools. As shown in Figure 5 and Table 2, we found that S100A2/S100A6/S100A8/S100A9/S100A10/S100A11/S100A13/S100A14/S100P high mRNA expressions were significantly associated with poor OS (overall survival). Besides, the high mRNA expressions of S100A5/S100A7/S100A7A/S100A12/S100G/S100Z were correlated with better OS. In addition, the other members

---

**Figure 3** | Correlation between S100s mRNA levels and tumor stage in HCC patients (GEPIA database). The mRNA levels of S100A2/S100A7/S100A7A/S100A8/S100A9/S100A11 were correlated with advanced tumor stage. A $p < 0.05$ was considered statistically significant.
of the S100s were found to have no correlations with the patient's survival. Based on the S100s mRNA expressions profiles mining above, we concluded that higher mRNA expressions of S100A6/S100A10/S100A11/S100A13/S100A14/S100P were found to be significantly associated with shorter OS, while higher expression of S100A12 was associated with favorable OS.

**Genetic Mutations in S100s and Their Associations With Survival of HCC Patients**

We further explored genetic alteration in S100s and their associations with survival by using the cBioPortal online tool\(^9\). As shown in Figure 6A, the mutation rate of S100s was really high in HCC patients. In the 360 enrolled samples, genetic mutations were discovered in 192 HCC patients which indicated a 53% mutation rate. S100A16, S100A13, S100A10 were the top three members with genetic mutations (the mutation rates were 24%, 21%, and 21%, respectively). Furthermore, high rate of genetic alteration in S100s correlated with shorter OS of HCC patients (Figure 6B, \( p = 0.0204 \)). Collectively, the above findings suggested that genetic alteration of S100s may have an impact on prognosis of HCC patients.

\(^9\)www.cbioportal.org

**Predicted Functions and Pathways of the Mutations in S100s and Their 50 Frequently Altered Neighbor Genes in HCC Patients**

We also explored the S100s correlations and networks with the online tool\(^9\). As was shown in Figure 6C, significant and positive correlations were observed between different S100s. Positive correlations were shown as red color while negative correlations showed blue. The numbers in the cells represent their correlation coefficient. We next explored the network for S100s and their 50 most associated genes. As shown in Figure 6D, the apoptotic-related genes, including TP53, TP63, TP73, BRCA1, NFKB1, MAPK1, MAPK3, and MAPK14 were correlated with S100s alterations. Moreover, functions and pathways of these genes were further explored by GO and KEGG in DAVID\(^11\). As was shown in Figure 7A, biological processes, such as innate immune response, positive regulation of transcription, positive regulation of NF-kappaB transcription factor activity, inflammatory response and apoptotic process were remarkably regulated by the S100s mutations in HCC. As was

\(^9\)www.cbioportal.org

\(^11\)https://david.ncifcrf.gov/summary.jsp
FIGURE 5 | The prognostic value of S100s mRNA expression in HCC patients (Kaplan-Meier Plotter). Higher mRNA expressions of S100A6/S100A10/S100A11/ S100A13/S100A14/S100P were shown to have shorter survival time, while higher expression of S100A12 was associated with longer survival time. OS, overall survival; DFS, disease-free survival. A $p < 0.05$ was considered statistically significant.

shown in Figure 7B, cellular components, including nucleus, cytoplasm, cytosol, extracellular exosome, and nucleoplasm were regulated by the S100s mutations in HCC. In addition, S100s mutations also regulated the molecular functions, such as protein binding, calcium ion binding, protein homodimerization activity, identical protein binding and transcription regulatory region DNA binding (Figure 7C). By KEGG analysis, pathways including Toll-like receptor signaling pathway and NF-kappa B signaling pathway (Figures 7D, 8) were found to be associated with S100s alterations.

The Association of S100s and Immune Infiltration Levels

We further explored the associations between S100s and immune infiltration levels in HCC by applying the TIMER online tool\(^1\). Spearman tests were used for analyzing the correlation coefficients. As shown in Figure 9, the expressions of S100A2/S100A3/S100A4/S100A5/S100A6/S100A8/S100A9/S100A10/S100A11/S100A13/S100A14/S100A16/S100B/S100P/S100Z were all shown to be closely associated with all six immune infiltrates (B cells, CD8$^+$ T cells, CD4$^+$ T cells, macrophages, neutrophils, and dendritic cells). For instance, S100A4 expression had significant positive correlations with all six immune infiltrates, especially B cells ($r = 0.548$, $P = 2.37E-28$), CD8$^+$ T cells ($r = 0.564$, $P = 4.17E-30$), macrophages ($r = 0.551$, $P = 1.61E-28$), and dendritic cells ($r = 0.665$, $P = 7.85E-45$). S100A6 expression had significant positive correlations with all six immune infiltrates, especially macrophages ($r = 0.532$, $P = 2.88E-26$). S100A11 expression had significant positive correlations with all six immune infiltrates, especially dendritic cells ($r = 0.566$, $P = 3.18E-30$). S100B expression had significant positive correlations with all six immune infiltrates, especially B cells ($r = 0.537$, $P = 4.56E-27$), CD8$^+$ T cells ($r = 0.528$, $P = 6.62E-26$) and dendritic cells ($r = 0.616$, $P = 6.97E-37$). Next, the associations between S100s and gene markers of different immune infiltrates were also investigated. As shown

\(^1\)https://cistrome.shinyapps.io/timer/
TABLE 2 | Prognosis roles of S100 family members (analyzed by Kaplan-Meier Plotter tools).

| S100 family members | OS | | | | | P | | | | | P |
|---------------------|----|----|----|----|----|---|----|----|----|---|---|
|                     | HR | 95%CI   |   | HR | 95%CI   |   |
| S100A1              | 0.71 | 0.49–1.04 | 0.075 | 1.42 | 1.04–1.94 | 0.028 |
| S100A2              | 1.74 | 1.22–2.49 | 0.0021 | 1.21 | 0.87–1.68 | 0.25 |
| S100A3              | 0.84 | 0.59–1.19 | 0.33 | 1.14 | 0.85–1.53 | 0.37 |
| S100A4              | 1.17 | 0.81–1.69 | 0.41 | 0.7 | 0.52–0.94 | 0.017 |
| S100A5              | 0.37 | 0.26–0.53 | 6.10E-09 | 0.54 | 0.41–0.73 | 3.30E-05 |
| S100A6              | 1.69 | 1.16–2.44 | 0.0051 | 0.87 | 0.65–1.17 | 0.35 |
| S100A7              | 0.48 | 0.34–0.68 | 2.60E-05 | 0.72 | 0.54–0.97 | 0.029 |
| S100A7A             | 0.37 | 0.26–0.52 | 4.50E-09 | 0.57 | 0.42–0.78 | 0.00027 |
| S100A8              | 1.48 | 1.03–2.13 | 0.032 | 1.32 | 0.96–1.82 | 0.088 |
| S100A9              | 2 | 1.39–2.88 | 0.00013 | 0.74 | 0.54–1.01 | 0.057 |
| S100A10             | 1.79 | 1.25–2.56 | 0.0012 | 1.57 | 1.17–2.11 | 0.0027 |
| S100A11             | 1.85 | 1.31–2.62 | 4.00E-04 | 0.68 | 0.5–0.93 | 0.014 |
| S100A12             | 0.64 | 0.44–0.91 | 0.014 | 0.85 | 0.62–1.17 | 0.33 |
| S100A13             | 1.45 | 1.03–2.05 | 0.034 | 1.29 | 0.95–1.77 | 0.1 |
| S100A14             | 1.58 | 1.01–2.46 | 0.42 | 1.33 | 0.97–1.83 | 0.078 |
| S100A16             | 1.39 | 0.99–1.97 | 0.058 | 1.3 | 0.96–1.75 | 0.089 |
| S100B               | 0.76 | 0.51–1.13 | 0.17 | 0.68 | 0.5–0.91 | 0.0093 |
| S100G               | 0.36 | 0.25–0.51 | 1.70E-09 | 0.6 | 0.45–0.8 | 0.00058 |
| S100P               | 1.63 | 1.16–2.31 | 0.0049 | 1.22 | 0.89–1.67 | 0.22 |
| S100Z               | 0.59 | 0.41–0.86 | 0.0049 | 0.56 | 0.41–0.76 | 0.00017 |

OS, overall survival; PFS, progression free survival. A P value < 0.05 was considered to be statistically significant and was shown in bold print.

FIGURE 6 | S100s gene expression and mutation analysis in HCC (cBioPortal) (A) S100s gene expression and mutation analysis in HCC. (B) High genetic alterations (53%) in S100s were associated with shorter OS. (C) Correlation between different S100s in HCC (Positive correlations were shown as red color while negative correlations showed blue. The numbers in the cells represented their correlation coefficient). (D) The network for S100s and the 50 most frequently altered neighbor genes.
FIGURE 7 | The functions of S100s and genes significantly associated with S100s alterations. GO functional enrichment analysis predicted three main functions of S100s mutations and their 50 frequently altered neighbor genes, including biological process, cellular components and molecular functions (A–C). KEGG pathway analysis on S100s and their 50 most frequently altered neighbor genes was shown at (D).

in Supplementary Table 1, significant associations between the S100s and markers of immune cells were found. In short, all the results above suggested that S100s played a critical role in immune infiltration of HCC.

DISCUSSION

S100s dysregulation has been seen in a variety of human malignancies (Allgower et al., 2020). Although the role of some members of S100s in the tumorigenesis and prognosis of several cancers has been partially confirmed, comprehensive understanding the role of twenty S100s in HCC has yet to be conducted. Our work aims to explore the expression, mutation, prognosis and associations with immune infiltration of S100s in HCC. We expect that our results will be helpful in improving existing knowledge, advancing treatment designs, and prognosis prediction.

In this study, our results showed that the mRNA levels of S100A4/S100A6/S100A10/S100A11/S100A13/S100A14/S100P were significantly upregulated in HCC patients, while the S100A8/S100A9/S100A12 mRNA levels were decreased. Survival analysis indicated that higher mRNA expressions of S100A6/S100A10/S100A11/S100A13/S100A14/S100P were shown to have shorter OS, while higher expression of S100A12 was associated with longer OS. Moreover, high mutation rate (53%) was found in S100s and correlated with poor survival. These findings suggested that S100A6/S100A10/S100A11/S100A12/S100A13/S100A14/S100P may be used as new prognostic or therapeutic biomarkers.

S100A4 is a well-known tumor promoting gene and is the most studied one in HCC. Overexpression of S100A4 led to heavier tumors and more metastasis sites, while down-regulation of S100A4 resulted in a reduction of proliferation and invasion of HCC cells (Yan et al., 2013). S100A4 regulates invasion and migration of HCC cells via NF-kappaB-dependent MMP9 signal (Zhang et al., 2013). It was also reported that S100A4 levels were significantly increased in HCC samples compared with controls, moreover, S100A4 protein levels correlated with tumor differentiation, invasion, recurrence and overall survival (Liu et al., 2013). Interestingly, in our study, we showed that both mRNA and protein expression of S100A4 were significantly higher in tumor tissues compared with non-tumor tissues. However, the S100A4 mRNA expression had no correlation with survival time in patients with HCC. One possible reason maybe the protein levels of S100A4 were elaborately controlled by post-transcriptional regulation. And the conclusion obtained here should be verified in further studies.

S100A6 is another well-studied member of S100s in cancer. S100A6 is upregulated in many kinds of tumors and may
Toll-like receptor signaling pathway and NF-kappa B signaling pathway regulated by the S100s alteration in HCC.

S100A6 is an oncogenic event in various malignancies, including thyroid anaplastic carcinoma, colorectal cancer and ovarian cancer (Ito et al., 2007; Suzuki and Tanigawara, 2014; Lokman et al., 2016). The role of S100A10 in HCC has rarely been explored. DNA microarray analysis of HCC identified S100A10 as one of the key members linked to integrin and Akt/NF-kappaB signaling (Kittaka et al., 2008). Shan et al. (2013) reported that miR-590-5p inhibited proliferation of HCC cells via down-regulating S100A10 expression. The expression of S100A10 in HCC cells was significantly increased than normal hepatic cells (Zhao et al., 2020). In our study,
FIGURE 9 | Association of 20 S100s genes with immune infiltration in HCC (TIMER). The expressions of S100A2/S100A3/S100A4/S100A5/S100A8/S100A10/S100A11/S100A13/S100A14/S100A16/S100B/S100P/S100Z were found to be significantly associated with the immune infiltrating levels of B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells. A \( p < 0.05 \) was considered statistically significant.

the results showed that the expression of S100A10 was significantly upregulated in HCC tissues than in para-tumor tissues. Moreover, high S100A10 mRNA expression correlated with poor prognosis.

S100A11 has dual roles in cell growth regulation, intracellular S100A11 inhibits cell growth and extracellular S100A11 promotes cell proliferation (Sakaguchi and Huh, 2011). S100A11 is reported to be associated with advanced tumor behavior and poor survival in bladder cancer (Yao et al., 2007). S100A11 activates Wnt/beta-catenin Signaling and promotes proliferation and migration of cervical cancer cells (Meng et al., 2019). In HCC, S100A11 was found to be a metastasis-associated protein by proteomic analysis (Song et al., 2006). Overexpression of S100A11 promotes migration of HCC cells (Luo et al., 2013). A recent study showed that S100A11 overexpression promoted inflammation/fibrosis and was associated with tumor grade and poor survival time of HCC patients (Sobolewski et al., 2020). In our study, the results showed that the expression of S100A11 was significantly upregulated in HCC tissues than in para-tumor tissues. Moreover, high S100A11 mRNA expression correlated with advanced tumor stage and poor prognosis.

S100A12 is commonly expressed on neutrophils monocytes and macrophages, the plasma levels of S100A12 are systemic biomarkers for many inflammatory diseases (Meijer et al., 2012). S100A12 is dysregulated in many types of cancers, upregulated in colorectal cancer and papillary thyroid cancer but reduced in gastric carcinoma and oropharyngeal squamous cells (Thierolf et al., 2008; Funk et al., 2015; Li et al., 2016; Wang et al., 2020). Studies on S100A12 in HCC are limited. Proteomics analysis indicated that S100A12 might be useful marker for predicting the early recurrence/metastasis of HCC after resection (Huang et al., 2014). Another study revealed that S100A12 was expressed not on HCC cells but intratumoral stroma cells and S100A12
overexpression predicted poor prognosis (Cai et al., 2018). In this study, the results showed that the mRNA expression of S100A12 in HCC tissues was significantly lower than that in normal tissues. Moreover, high S100A12 expression correlated with favorable OS in patients with HCC.

There are limited studies on S100A13 in cancer. S100A13 was first identified as a powerfully angiogenic biomarker in some kinds of tumor such as melanoma and gliomas (Landriscina et al., 2006; Massi et al., 2010). A recent study showed that S100A13 overexpression promoted migration of lung cancer cells (Pierce et al., 2008). Consistent with these results, the results showed that the expression of S100A13 was significantly upregulated in HCC tissues than in para-tumor tissues. Moreover, high S100A13 mRNA expression correlated with poor prognosis.

S100A14, a novel member of the S100s, has been characterized by differentially expressed and functioned in various cancer types. Overexpression of S100A14 has been found in some kinds of cancers, such as breast cancer, lung cancer and bladder cancer. But downregulated in some other kinds of cancers, for example colorectal carcinoma and renal cancer (Basnet et al., 2019). S100A14 activates ERK and NF-κB signaling and promotes ESCC cell proliferation. However, in oral squamous cell carcinoma, S100A14 positively affects the function of p53 and inhibits cell proliferation (Jin et al., 2011; Sapkota et al., 2012). Few studies investigated the role of S100A14 in HCC. Zhao et al. (2013) reported that knock-down of S100A14 decreased proliferation and invasion of HCC cells. Similar to these results, the results showed that the expression of S100A14 was significantly upregulated in HCC tissues than in para-tumor tissues. Moreover, high S100A14 mRNA expression correlated with poor prognosis.

S100P is an oncogenic event in many types of tumors, including pancreatic adenocarcinoma, breast cancer and ovarian cancer (Wang et al., 2006; Ezzat et al., 2016; Bai et al., 2018). In ovarian cancer, S100P was shown to be positively correlated with CA125 and poor prognosis (Wang et al., 2015). Studies investigating the role of S100P in HCC were limited. S100P was found to be overexpressed in HCC tissues and correlated with advanced tumor behavior and poor prognosis (Yuan et al., 2013). Another study showed that S100P was useful predictor for microvascular invasion and portal vein tumor thrombus (Qi et al., 2021). Similar to these results, our findings showed that the expression of S100P was significantly upregulated in HCC tissues than in para-tumor tissues. Moreover, high S100P mRNA expression correlated with poor prognosis.

HCC is now generally considered as an immunogenic tumor (Pardee and Butterfield, 2012). Various immune cells have been proved to affect the progression and prognosis of HCC. For instance, tumor-associated macrophages (TAMs) and tumor infiltrations of neutrophils are associated with poor prognosis in patients with HCC, while CD8 + cytotoxic T lymphocytes (CTLs) and dendritic cells (DCs) were predictive for better prognosis (Chen et al., 2020). In this study, our results indicated that S100s played a critical role in immune infiltration of HCC. Especially, both S100A4 and S100A6 had strong positive correlations with macrophages. Therefore, the combination these S100s inhibitors with immunotherapies may be a promising strategy in HCC therapy.

Nevertheless, our study had some limitations. First, all the data included for analysis were retrieved from online databases, further researches are still required to verify these findings. Second, all survival analyses were conducted by the Kaplan-Meier database, the independent prognostic values of S100s by multivariate analysis were not acquired because of data limitation. Third, exploring the detailed mechanism of each S100 in HCC was not conducted in this research, future researches are still needed.

In conclusion, in this study, we systemically explored the expression, mutations, predictive signaling pathways, prognosis and associations with immune infiltration of different S100s in patients with HCC. Our research gives new insights regarding the roles of S100s in HCC and may be helpful for the further combination of immunotherapies with S100s inhibitors in HCC.

**DATA AVAILABILITY STATEMENT**

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

**ETHICS STATEMENT**

Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

**AUTHOR CONTRIBUTIONS**

BZ and XXie contributed to the study design and critical revision of the manuscript. SZ, LL, and TX carried out the study and drafted the manuscript. Cj, XXu, YW, and MW analyzed the data. All authors read and approved the final manuscript.

**FUNDING**

This research was supported by grants from the Medical and Health Project of Xiamen City (Key Project, No. 3502Z20191105).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2021.648156/full#supplementary-material

**Supplementary Table 1** | Correlations between S100s genes and markers of immune cells in HCC.
REFERENCES

Allemanci, C., Weir, H. K., Carreira, H., Farewood, R., Spika, D., and Wang, X. S. (2015). Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (condorc-2). Lancet 385, 977–1010. doi: 10.1016/s0140-6736(14)62038-9

Allgorwer, C., Kretz, A. L., von Karstedt, S., Wittau, M., Henne-Bruns, D., et al. (2020). Friend or foe: s100 proteins in cancer. Cancers 12:2037. doi: 10.3390/cancers12082307

Asplund, A., Edqvist, P. H., Schwenk, J. M., and Ponten, F. (2012). Antibodies for profiling the human prostate—the human protein atlas as a resource for cancer research. Proteomics 12, 2067–2077. doi: 10.1002/pmic.201110054

Bai, Y., Li, L. D., Li, J., and Lu, X. (2018). Prognostic values of s100 family members in ovarian cancer patients. BMC Cancer 18:1256. doi: 10.1186/s12885-018-5170-3

Basnet, S., Sharma, S. D., Costea, D. E., and Sapkota, D. (2019). Expression profile and functional role of s100a14 in human cancer. Oncotarget 10, 2996–3012. doi: 10.18632/oncotarget.26861

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., and Jemal, A., et al. (2018). Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424. doi: 10.3322/caac.21492

Bresnick, A. R., Weber, D. J., and Zimmer, D. B. (2015). S100 proteins in cancer. Nat. Rev. Cancer 15, 96–109. doi: 10.1038/nrc3893

Cai, H., Ye, B. G., Ao, J. Y., Zhu, X. D., Zhang, Y. Y., Choi, Z. D., et al. (2018). High expression of s100a14 on intrauterine stroma cells indicates poor prognosis following surgical resection of hepatocellular carcinoma. Oncol. Lett. 16, 5398–5404. doi: 10.3892/ol.2018.9270

Chen, X., Cheung, S. T., So, S., Fan, S. T., Barry, C., Higgins, J., et al. (2002). Gene expression patterns in human liver cancers. Mol. Biol. Cell 13, 1929–1939. doi: 10.1091/mbc.02-02-0023

Chen, Y. R., Ouyang, S. S., Chen, Y. L., Li, P., Xu, H. W., Zhu, A. L., et al. (2020). De Ponti, A., Wiechert, L., Schneller, D., Pusterla, T., Longerich, T., Hogg, N., Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., et al. Funk, S., Mark, R., Bayo, P., Flechtenmacher, C., Grabe, N., Plinkert, P. K., et al. (2017). Proteomics analysis of early recurrence/metastasis of huge hepatocellular carcinoma following radical resection. Proteome Sci. 12:22. doi: 10.1186/1477-5956-12-22

Ito, Y., Arai, K., Nozawa, R., Yoshida, H., Higashiyama, T., et al. (2007). S100a10 expression in thyroid neoplasms originating from the follicular epithelium: contribution to the aggressive characteristic of anaplastic carcinoma. Anticancer Res. 27, 2679–2683.

Jin, Q., Chen, H., Luo, A., Ding, F., and Liu, Z. (2011). S100a14 stimulates cell proliferation and induces cell apoptosis at different concentrations via receptor for advanced glycation end products (rage). PLoS One 6:e19375. doi: 10.1371/journal.pone.019375

Katsanos, K., Kitrou, P., Spiliopoulos, S., Maroulis, I., Petsas, T., Karnabatidis, D., et al. (2017). Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: a network meta-analysis of randomized controlled trials. PLoS One 12:e184597. doi: 10.1371/journal.pone.0184597

Kittaka, N., Takemasa, I., Takeda, Y., Marubashi, S., Nagano, H., Umeshita, K., et al. (2008). Molecular mapping of human hepatocellular carcinoma provides deeper biological insight from genomic data. Eur. J. Cancer 44, 885–897. doi: 10.1016/j.ejca.2008.02.019

Landriscina, M., Schinanzi, G., Di Leonardo, G., Quirino, M., Cassano, A., D’Argento, E., et al. (2006). S100a13, a new marker of angiogenesis in human astrocytic gliomas. J. Neurooncol. 80, 251–259. doi: 10.1007/s10937-006-9189-y

Li, D., Zheng, Z., Yu, T., Qin, J., Wu, J., Song, J.-C., et al. (2016). Expression and clinical implication of s100a12 in gastric carcinoma. Tumour Biol. 37, 6551–6559. doi: 10.1007/s13277-015-4460-5

Li, T., Fan, J., Wang, B., Traugh, N., Chen, Q., Liu, J., et al. (2017). Timer: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 77, e108–e110. doi: 10.1158/0008-5472.CAN-17-0307

Li, Z., Tang, M., Ling, B., Liu, S., Zheng, Y., Nie, C., et al. (2014). Increased expression of s100a6 promotes cell proliferation and migration in human hepatocellular carcinoma. J. Mol. Med. 92, 291–303. doi: 10.1007/s00109-013-1104-3

Liu, S., Wang, W., Zhao, Y., Liang, K., and Huang, Y. (2020). Identification of potential key genes for pathogenesis and prognosis in prostate cancer by integrated analysis of expression profiles and the cancer genome atlas. Front. Oncol. 10:809. doi: 10.3389/fonc.2020.00809

Liu, Z., Liu, H., Pan, D., Gu, Q., and Liang, J. (2013). Clinicopathological significance of s100a4 expression in human hepatocellular carcinoma. J. Int. Med. Res. 41, 457–462. doi: 10.1177/0300060513478086

Lokman, N. A., Pyrgi, C. E., Ruszkiewicz, A., Oehler, M. K., and Ricciardelli, C. (2016). Annexin a2 and s100a10 are independent predictors of serous ovarian cancer outcome. Transl. Res. 171, 83–95. doi: 10.1016/j.trsl.2016.02.002

Luo, X., Xie, H., Long, X., Zhou, M., Xu, Z., Shi, B., et al. (2013). Egf2 mediates hepatocellular carcinoma cell invasion by promoting s100 calcium binding protein a11 expression. PLoS One 8:e83332. doi: 10.1371/journal.pone.0083332

Mas, V. R., Maluf, D. G., Archer, K. J., Yanek, K., Kulik, L., and Long, P. (2009). Genes involved in viral carcinogenesis and tumor initiation in hepatitis c virus-induced hepatocellular carcinoma. Mol. Med. 15, 85–94. doi: 10.2119/molmed.2008.0110

Massi, D., Landriscina, M., Piscazio, A., Cosci, E., Kirov, A., and Paglierani, M., et al. (2010). S100a13 is a new angiogenic marker in human melanoma. Med. Pathol. 23, 804–813. doi: 10.1093/molpath/dp005.2010.54

Meijer, B., Geary, R. B., and Day, A. S. (2012). The role of s100a12 as a systemic marker of inflammation. Int. J. Inflam. 2012:907078. doi: 10.1155/2012/907078

Meng, M., Sang, L., and Wang, X. (2019). S100 calcium binding protein a11 (s100a11) promotes the proliferation, migration and invasion of cervical cancer cells, and activates wnt/beta-catenin signaling. Onco. Targets Ther. 12, 8675–8685. doi: 10.2147/OTT.S22548

Pardeed, A. D., and Butterfield, L. H. (2012). Immunotherapy of hepatocellular carcinoma: unique challenges and clinical opportunities. Oncotarget 3, 4431. doi: 10.18632/oncotarget.22284

Prostate. 44, 151–159. doi: 10.1016/j.ijcancer.2007.10.017

Qi, L. N., Ma, L., Wu, F. X., Chen, Y. Y., Xing, W. T., Ziang, Z.-J., et al. (2021). S100p as a novel biomarker of microvascular invasion and portal vein tumor invasion.
thrombus in hepatocellular carcinoma. *Hepatol. Int.* 15, 114–126. doi: 10.1007/s12072-020-10330-1

Rhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., et al. (2004). Oncomine: a cancer microarray database and integrated data-mining platform. *Neoplasia* 6, 1–6. doi: 10.1016/S1547-5568(04)80047-2

Roessler, S., Jia, H. L., Budhu, A., Forgues, M., Ye, Q. H., Lee, J.-S., et al. (2010). A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. *Cancer Res.* 70, 10202–10212. doi: 10.1158/0008-5472.CAN-10-2607

Sakaguchi, M., and Huh, N. H. (2011). S100a11, a dual growth regulator of epidermal keratinocytes. *Amino Acids* 41, 797–805. doi: 10.1007/s00726-010-0747-4

Sapkota, D., Costea, D. E., Blo, M., Bruland, O., Lorenz, J. B., Vastrstrand, E. N., et al. (2012). S100A14 inhibits proliferation of oral carcinoma derived cells through G1-arrest. *Oral Oncol.* 48, 219–225. doi: 10.1016/j.oraloncology.2011.10.001

Shan, X., Miao, Y., Fan, R., Qian, H., Chen, P., Liu, H., et al. (2013). Mir-590-5p inhibits growth of HepG2 cells via decrease of S100A10 expression and inhibition of the Wnt pathway. *Int. J. Mol. Sci.* 14, 8556–8569. doi: 10.3390/ijms14085856

Sobolewski, C., Abegg, D., Berthou, F., Dolicka, D., Calo, N., Sempoux, C., et al. (2020). S100A11/ANXA2 belongs to a tumour suppressor/oncogene network deregulated early with steatosis and involved in inflammation and hepatocellular carcinoma development. *Gut* 69, 1841–1854. doi: 10.1136/gutjnl-2019-319019

Song, H. Y., Liu, Y. K., Peng, J. T., Cui, J. F., Dai, Z., Zhang, L., et al. (2006). Proteomic analysis on metastasis-associated proteins of human hepatocellular carcinoma tissues. *J. Cancer Res. Clin. Oncol.* 132, 92–98. doi: 10.1007/s00432-005-0044-x

Suzuki, S., and Tanigawara, Y. (2014). Forced expression of S100A10 reduces sensitivity to oxaliplatin in colorectal cancer cells. *Proteome Sci.* 12:26. doi: 10.1186/1477-5956-12-26

Tang, Z., Li, C., Kang, B., Gao, G., Li, C., Zhang, Z., et al. (2017). Gepia: a web server for cancer and normal gene expression profiling and interactive analyses. *Nucleic Acids Res.* 45, W98–W102. doi: 10.1093/nar/gkx247

Tao, R.; Wang, Z. F., Qiu, W., He, Y. F., Yan, W. Q., Sun, W.-Y., et al. (2017). Role of S100A3 in human hepatocellular carcinoma and the anticancer effect of sodium caranthinate. *Exp. Ther. Med.* 13, 2812–2818. doi: 10.3892/etm.2017.4294

Thierolf, M., Hagmann, M. L., Pfeffer, M., Bernentis, N., Wild, N., Roehrler, M., et al. (2008). Towards a comprehensive proteome of normal and malignant human colon tissue by 2-d-ic-esi-ms and 2-de proteomics and identification of S100A12 as potential cancer biomarker. *Proteomics Clin. Appl.* 2, 11–22. doi: 10.1002/prca.200780046

Wang, G., Platt-Higgins, A., Carroll, J., de Silva, R. S., Winstanley, J., Barracough, R., et al. (2006). Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients. *Cancer Res.* 66, 1199–1207. doi: 10.1158/0008-5472.CAN-05-2605

Wang, X., Chen, L., and Zeng, Y. (2001). Calcium-binding protein S100A2 in the retardation of growth and proliferation of hepatocellular carcinoma cells. *Zhonghua Zhong Liu Za Zhi* 23, 363–365.

Wang, X., Sun, Z., Tian, W., Piao, C., Xie, X., Zang, J., et al. (2020). S100A12 is a promising biomarker in papillary thyroid cancer. *Sci. Rep.* 10:1724. doi: 10.1038/s41598-020-58534-1

Wang, X., Tian, T., Li, X., Zhao, M., Lou, Y., Qian, J., et al. (2015). High expression of S100P is associated with unfavorable prognosis and tumor progression in patients with epithelial ovarian cancer. *Am. J. Cancer Res.* 5, 2409–2421.

Wurmback, E., Chen, Y. B., Khitrov, G., Zhang, W., Roayaie, S., Schwartz, M., et al. (2007). Genome-wide molecular profiles of hcv-induced dysplasia and hepatocellular carcinoma. *Hepatology* 45, 938–947. doi: 10.1002/hep.21622

Xue, T. C., Zhang, B. H., Ye, S. L., and Ren, Z. G. (2015). Differentially expressed gene profiles of intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and combined hepatocellular-cholangiocarcinoma by integrated microarray analysis. *Tumour Biol.* 36, 5891–5899. doi: 10.1007/s13277-015-2621-1

Yan, X. L., Jia, Y. L., Chen, L., Zeng, Q., Zhou, J. N., Fu, C. J., et al. (2013). Hepatocellular carcinoma-associated mesenchymal stem cells promote hepatocarcinoma progression: role of the S100A4-mir155-5p-c-myc axis. *Hepatology* 57, 2274–2286. doi: 10.1002/hep.26257

Yao, R., Davidson, D. D., Lopez-Beltran, A., MacLennan, G. T., Montironi, R., Cheng, L., et al. (2007). The S100 proteins for screening and prognostic grading of bladder cancer. *Histol. Histopathol.* 22, 1025–1032.

Yuan, R. H., Chang, K. T., Chen, Y. L., Hsu, H. C., Lee, P. H., Lai, P. L., et al. (2013). S100P expression is a novel prognostic factor in hepatocellular carcinoma and predicts survival in patients with high tumor stage or early recurrent tumors. PLoS One 8:e65501. doi: 10.1371/journal.pone.0065501

Zhang, J., Zhang, D. L., Jiao, X. L., and Dong, Q. (2013). S100A4 regulates migration and invasion in hepatocellular carcinoma HepG2 cells via NF-kappab-dependent MMP-9 signal. *Eur. Rev. Med. Pharmacol. Sci.* 17, 2372–2382.

Zhao, F. T., Jia, Z. S., Yang, Q., Song, L., and Jiang, X. J. (2013). S100A14 promotes the growth and metastasis of hepatocellular carcinoma. *Asian Pac J. Cancer Prev.* 14, 3831–3836. doi: 10.7314/APJCP.2013.14.6.3831

Zhao, J., Chi, B. J., Sun, Y., Chi, N. N., Zhang, X. M., Sun, J.-B., et al. (2020). LINC00174 is an oncogetic IncRNA of hepatocellular carcinoma and regulates miR-320/S100A10 axis. *Cell Biochem. Funct.* 38, 859–869. doi: 10.1002/cbf.3498

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Zheng, Liu, Xue, Jing, Xu, Wu, Wang, Xie and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.